MY153231A - Diamine derivatives - Google Patents

Diamine derivatives

Info

Publication number
MY153231A
MY153231A MYPI20022307A MYPI20022307A MY153231A MY 153231 A MY153231 A MY 153231A MY PI20022307 A MYPI20022307 A MY PI20022307A MY PI20022307 A MYPI20022307 A MY PI20022307A MY 153231 A MY153231 A MY 153231A
Authority
MY
Malaysia
Prior art keywords
thrombus formation
syndrome
infarction
group
pulmonary
Prior art date
Application number
MYPI20022307A
Other languages
English (en)
Inventor
Toshiharu Ohta
Noriyasu Haginoya
Kenji Yoshikawa
Masatoshi Nagamochi
Syozo Kobayashi
Makoto Ono
Satoshi Komoriya
Toshiharu Yoshino
Kouichi Uoto
Yumi Nakamoto
Hiroyuki Naito
Akiyoshi Mochizuki
Tsutomu Nagata
Hideyuki Kanno
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27482359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY153231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MY153231A publication Critical patent/MY153231A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI20022307A 2001-06-20 2002-06-19 Diamine derivatives MY153231A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001187105 2001-06-20
JP2001243046 2001-08-09
JP2001311808 2001-10-09
JP2001398708 2001-12-28
PCT/JP2002/002683 WO2003000657A1 (en) 2001-06-20 2002-03-20 Diamine derivatives

Publications (1)

Publication Number Publication Date
MY153231A true MY153231A (en) 2015-01-29

Family

ID=27482359

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20022307A MY153231A (en) 2001-06-20 2002-06-19 Diamine derivatives

Country Status (12)

Country Link
US (7) US7365205B2 (show.php)
EP (1) EP2343290A1 (show.php)
AR (1) AR036102A1 (show.php)
BE (1) BE2015C046I2 (show.php)
CY (2) CY1113054T1 (show.php)
FR (1) FR15C0068I2 (show.php)
MY (1) MY153231A (show.php)
NL (1) NL300760I2 (show.php)
PT (1) PT1405852E (show.php)
TW (1) TWI298066B (show.php)
WO (1) WO2003000657A1 (show.php)
ZA (1) ZA200309866B (show.php)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2003000657A1 (en) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
CN1826333B (zh) * 2001-06-20 2012-12-26 第一三共株式会社 二胺衍生物
AU2002328596B2 (en) * 2001-08-09 2007-09-20 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2004058715A1 (ja) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. ジアミン誘導体
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
EP1670739A4 (en) * 2003-10-08 2007-08-08 Bristol Myers Squibb Co CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
KR101215153B1 (ko) 2003-11-12 2012-12-24 다이이찌 산쿄 가부시키가이샤 티아졸 유도체의 제조법
BRPI0418244A (pt) * 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
MXPA06014573A (es) * 2004-06-24 2007-03-12 Incyte Corp Compuestos amido y su uso como farmaceuticos.
EP1768954A4 (en) * 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
AU2005258248A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
EP1773773A4 (en) * 2004-06-24 2009-07-29 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
EA200700251A1 (ru) * 2004-08-10 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве фармацевтических средств
US7499687B2 (en) * 2004-11-09 2009-03-03 Theta Microelectronics, Inc. Wireless transmitter DC offset recalibration
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
WO2006055752A2 (en) * 2004-11-18 2006-05-26 Incyte Corporation INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME
JP2009505943A (ja) * 2005-02-18 2009-02-12 アルパイダ アーゲー ２ｈ−クロメンの製造のための新規方法
BRPI0609419A2 (pt) * 2005-03-31 2010-03-30 Daiichi Sankyo Co Ltd derivados de tiamina
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007032371A1 (ja) 2005-09-14 2007-03-22 Dainippon Sumitomo Pharma Co., Ltd. 摂食調節剤としてのオキシインドール誘導体
WO2007032498A1 (ja) * 2005-09-16 2007-03-22 Daiichi Sankyo Company, Limited 光学活性なジアミン誘導体およびその製造方法
US20070066584A1 (en) * 2005-09-21 2007-03-22 Wenqing Yao Amido compounds and their use as pharmaceuticals
CA2630492C (en) * 2005-12-05 2015-04-14 Incyte Corporation Spiro-lactam compounds
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
JP2009525333A (ja) * 2006-01-31 2009-07-09 インサイト・コーポレイション アミド化合物およびその医薬としての使用
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
EP2018378A2 (en) * 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US8344180B2 (en) 2006-08-30 2013-01-01 Shionogi & Co., Ltd. Hydrazine amide derivative
AU2008206039A1 (en) * 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
PL2140867T5 (pl) * 2007-03-29 2023-10-30 Daiichi Sankyo Company, Limited Kompozycja farmaceutyczna
KR101581289B1 (ko) 2007-05-31 2015-12-31 세프라코 아이엔시. 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010053583A2 (en) * 2008-11-10 2010-05-14 Dana Farber Cancer Institute Small molecule cd4 mimetics and uses thereof
CN102317248A (zh) 2008-12-12 2012-01-11 第一三共株式会社 光学活性羧酸的生产方法
RU2464271C1 (ru) 2008-12-17 2012-10-20 Дайити Санкио Компани, Лимитед Способ получения производного диамина
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
WO2010104078A1 (ja) * 2009-03-10 2010-09-16 第一三共株式会社 ジアミン誘導体の製造方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
WO2010131663A1 (ja) * 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
TW201102064A (en) 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
FR2948372B1 (fr) 2009-07-21 2011-07-22 Servier Lab Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
JP5749247B2 (ja) * 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
EP2540317A4 (en) 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
ES2600894T3 (es) 2010-02-22 2017-02-13 Daiichi Sankyo Company, Limited Preparación sólida de liberación sostenida para uso oral
JP5692873B2 (ja) * 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CN103619883A (zh) 2011-01-19 2014-03-05 拜耳知识产权有限责任公司 凝血因子抑制剂的结合蛋白
EP2730269B1 (en) 2011-07-08 2017-08-23 Daiichi Sankyo Company, Limited Product quality control method
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN102659757B (zh) * 2012-04-24 2013-11-06 南京药石药物研发有限公司 一种合成5-氯-3-噻吩甲醛的中间体及其制备方法
BR112015004190A2 (pt) 2012-09-03 2017-07-04 Daiichi Sankyo Co Ltd composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada
BR112015004666B1 (pt) 2012-09-07 2022-04-26 Novartis Ag Derivados de indol carboxamida, seu uso, e composição farmacêutica
CN104781244A (zh) 2012-11-23 2015-07-15 第一三共株式会社 用于制备(1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛烷-7-酮的方法
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
CN104936961B (zh) * 2013-03-29 2016-10-26 第一三共株式会社 (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
JP2016529279A (ja) 2013-08-29 2016-09-23 第一三共株式会社 がんの治療又は予防のための剤
JP2017509622A (ja) 2014-03-31 2017-04-06 第一三共株式会社 抗凝固薬として使用されるビタミンＫ拮抗薬に感受性を有する患者における、出血事象及び関連障害を治療及び予防するための第Ｘａ因子阻害薬の使用
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
CN104529729B (zh) * 2014-12-31 2016-03-30 浙江永太科技股份有限公司 一种2-氟-3-氯苯甲醛的制备方法
TWI571460B (zh) 2016-03-14 2017-02-21 中化合成生技股份有限公司 二胺衍生物之製造方法
WO2018011823A1 (en) 2016-07-13 2018-01-18 Mylan Laboratories Limited Salt of amine-protected (1s,2r,4s)-1,2-amino-n,n-dimethylcyclohexane-4-carboxamide
WO2018069769A1 (en) 2016-10-13 2018-04-19 Daiichi Sankyo Company, Limited Pharmaceutical composition for inhibiting neointima formation of blood vessel
US10301322B2 (en) 2016-12-27 2019-05-28 Apotex Inc. Processes for the preparation of edoxaban and intermediates thereof
CN110770224B (zh) 2017-03-10 2022-11-18 罗格斯新泽西州立大学 作为外排泵抑制剂的吲哚衍生物
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
CN118903456A (zh) 2018-09-26 2024-11-08 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
EP3854816A4 (en) 2018-09-30 2022-09-07 Jiangsu Hengrui Medicine Co., Ltd. ANTI-B7H3 ANTIBODY EXATECAN ANALOGUE CONJUGATE AND ITS MEDICAL USE
CN109942600B (zh) * 2019-04-15 2021-08-20 内蒙古京东药业有限公司 一种依度沙班的制备方法
US20220251112A1 (en) * 2019-07-04 2022-08-11 Glenmark Life Sciences Limited Process for preparation of edoxaban
US20220315545A1 (en) 2019-07-10 2022-10-06 Bayer Aktiengesellschaft Process of preparing 2-(phenylimino)-1,3-thiazolidin-4-ones
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
CN118403182A (zh) 2019-12-12 2024-07-30 江苏恒瑞医药股份有限公司 抗密蛋白抗体药物偶联物及其医药用途
MX2022008474A (es) 2020-01-22 2022-08-02 Jiangsu Hengrui Medicine Co Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo.
EP4130045A4 (en) 2020-03-25 2023-12-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AN ANTIBODY-DRUG CONJUGATE
WO2021190581A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
TWI888517B (zh) 2020-03-25 2025-07-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｓｍａ抗體-依喜替康類似物偶聯物及其醫藥用途
MX2022015695A (es) 2020-06-08 2023-03-21 Baili Bio Chengdu Pharmaceutical Co Ltd Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma.
KR102908792B1 (ko) 2020-12-18 2026-01-07 엠에프씨 주식회사 디아민 유도체의 제조방법
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
CN116178251A (zh) * 2021-11-26 2023-05-30 上海汇伦医药股份有限公司 一种依度沙班中间体的制备方法
IL313262A (en) 2021-12-03 2024-08-01 Systimmune Inc Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
CN114456194B (zh) * 2021-12-14 2023-07-07 浙江九洲药业股份有限公司 甲苯磺酸艾多沙班的中间体及其制备方法
CN115583900A (zh) * 2022-04-29 2023-01-10 张邦成都生物医药科技有限公司 一种高纯度依度沙班中间体的制备方法
WO2023223346A1 (en) 2022-05-16 2023-11-23 Mylan Laboratories Limited An improved process for the preparation of edoxaban intermediate
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
CN115724792A (zh) 2022-11-24 2023-03-03 上海柏狮生物科技有限公司 一种依度沙班关键中间体及其合成方法
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354120A (en) * 1964-02-26 1967-11-21 Monsanto Co Polyamides prepared from 5, 5'-diaminoindigo
WO1986007257A2 (en) 1985-06-07 1986-12-18 The Upjohn Company Antiarrhythmic use for aminocycloalkylamides
AU8501291A (en) 1990-09-10 1992-03-30 Upjohn Company, The Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
IL100576A (en) 1991-01-18 1995-11-27 Eli Lilley And Company Cephalosporin antibiotics
WO1993010022A1 (en) 1991-11-14 1993-05-27 Frutin Bernard D A pressurised container
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
EP0687249A1 (en) 1993-03-03 1995-12-20 Eli Lilly And Company Balanoids
DE69410193T2 (de) 1993-03-17 1998-09-03 Meiji Seika K.K., Tokio/Tokyo Neue verbindungen mit blutplättchenaggregationshemmender aktivität
KR970001164B1 (ko) 1993-06-09 1997-01-29 한국과학기술연구원 세팔로스포린계 항생제 및 그의 제조방법
DE69426602T2 (de) 1993-10-19 2001-08-30 Sumitomo Pharmaceuticals Co., Ltd. 2,3-diaminopropionsäurederivate
TW270114B (show.php) 1993-10-22 1996-02-11 Hoffmann La Roche
US5525042A (en) 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
AU6856094A (en) 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
IL117805A0 (en) 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
ZA963391B (en) 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
WO1997038984A1 (en) 1996-04-17 1997-10-23 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
IL128428A0 (en) 1996-08-14 2000-01-31 Zeneca Ltd Substituted pyrimidine derivatives and their pharmaceutical use
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
JP2001511798A (ja) 1997-02-13 2001-08-14 ゼネカ・リミテッド オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
AU7453498A (en) 1997-05-30 1998-12-30 Takeda Chemical Industries Ltd. Sulfonamide derivatives, their production and use
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
EP1007037A4 (en) 1997-06-26 2004-10-06 Lilly Co Eli ANTITHROMBOTIC AGENTS
EP1014962A4 (en) 1997-06-26 2007-06-27 Lilly Co Eli ANTITHROMBOTIC AGENTS
ATE306261T1 (de) 1997-06-26 2005-10-15 Lilly Co Eli Antithrombosemittel
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
WO1999016747A1 (en) 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US6130349A (en) * 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DE19814801A1 (de) 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
GB9807104D0 (en) 1998-04-02 1998-06-03 Chirotech Technology Ltd The preparation of phosphine ligands
NZ507567A (en) 1998-04-21 2003-08-29 Du Pont Pharm Co 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents
PL343706A1 (en) 1998-05-02 2001-08-27 Astrazeneca Ab Heterocyclic derivatives which inhibit factor xa
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
GB9809350D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Novel salt
WO2000000498A1 (en) 1998-06-30 2000-01-06 Chirotech Technology Limited The preparation of arylphosphines
JP2000086659A (ja) 1998-07-14 2000-03-28 Takeda Chem Ind Ltd オクタヒドロピリド［１，２―ａ］ピラジン誘導体
TW434207B (en) 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
US6747023B1 (en) 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
ES2196917T3 (es) 1998-12-23 2003-12-16 Lilly Co Eli Amidas heteroaromaticas como inhibidores del factor xa`.
DE69931393T2 (de) 1998-12-23 2007-03-29 Eli Lilly And Co., Indianapolis Antithrombotische amide
EP1140903B1 (en) 1998-12-23 2004-08-04 Eli Lilly And Company Aromatic amides
DE69915687T2 (de) 1998-12-24 2005-02-10 Eli Lilly And Co., Indianapolis Heterocyclische amide als inhibitoren von faktor xa
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
AU2241400A (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
GB9909592D0 (en) * 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
EP1185512A2 (en) 1999-05-24 2002-03-13 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
AU6448200A (en) 1999-06-15 2001-01-02 Rhodia Chimie Sulphonylamides and carboxamides and their use in asymmetrical catalysis
GB9914342D0 (en) 1999-06-19 1999-08-18 Zeneca Ltd Compound
JP2001011071A (ja) 1999-06-25 2001-01-16 Mochida Pharmaceut Co Ltd アミノアルキルスルホンアミド誘導体
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
GB9917344D0 (en) 1999-07-24 1999-09-22 Zeneca Ltd Novel salt
DK1212300T3 (da) 1999-09-13 2004-03-15 Dimensional Pharm Inc Azacyclololalkanonserinproteaseinhibitorer
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
HU230773B1 (hu) 1999-09-17 2018-03-28 Millennium Pharmaceuticals, Inc. Benzamidok és rokon Xa faktor inhibitorok
CA2392576A1 (en) 1999-11-24 2001-05-31 Lingyan Wang .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
CA2413241A1 (en) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
CA2422873A1 (en) 2000-09-29 2002-04-04 Wenhao Li Piperazin-2-one amides as inhibitors of factor xa
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
AU2001294824A1 (en) 2000-09-29 2002-04-08 Millennium Pharmaceuticals, Inc. Piperazine based inhibitors of factor xa
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CN1283626C (zh) 2000-11-22 2006-11-08 安斯泰来制药有限公司 取代苯衍生物或其盐
JP2004523534A (ja) 2000-12-20 2004-08-05 ブリストル−マイヤーズ　スクイブ　カンパニー ケモカイン受容体活性調節剤としての環状誘導体
DE60221505D1 (de) 2001-03-30 2007-09-13 Millennium Pharm Inc FAKTOR Xa BENZAMIDIN INHIBITOREN
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
CN1826333B (zh) * 2001-06-20 2012-12-26 第一三共株式会社 二胺衍生物
AU2002328596B2 (en) 2001-08-09 2007-09-20 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
SI1427415T1 (sl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
WO2004058728A1 (ja) * 2002-12-24 2004-07-15 Daiichi Pharmaceutical Co., Ltd. 新規なエチレンジアミン誘導体
WO2004058715A1 (ja) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. ジアミン誘導体

Also Published As

Publication number Publication date
WO2003000657A1 (en) 2003-01-03
CY2015034I2 (el) 2016-04-13
HK1092461A1 (en) 2007-02-09
ZA200309866B (en) 2005-03-30
TWI298066B (en) 2008-06-21
US20100093785A1 (en) 2010-04-15
US20110312990A1 (en) 2011-12-22
CY1113054T1 (el) 2016-04-13
FR15C0068I2 (fr) 2016-04-22
BE2015C046I2 (show.php) 2021-07-19
US20090270446A1 (en) 2009-10-29
PT1405852E (pt) 2012-10-30
US20050119486A1 (en) 2005-06-02
NL300760I2 (en) 2017-07-20
US20080015215A1 (en) 2008-01-17
US7365205B2 (en) 2008-04-29
US20110077266A1 (en) 2011-03-31
US7342014B2 (en) 2008-03-11
FR15C0068I1 (show.php) 2015-12-04
EP2343290A1 (en) 2011-07-13
US20050020645A1 (en) 2005-01-27
CY2015034I1 (el) 2016-04-13
AR036102A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
MY153231A (en) Diamine derivatives
MXPA05006989A (es) Derivados de diamina.
BR0210541A (pt) Derivados diamìnicos
WO2003016302A1 (en) Diamine derivatives
RU2345993C2 (ru) ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
BR0316585A (pt) Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
YU205590A (sh) Amidi imidazo (4,5-b)hinolinoloksi alkanovih kiselina sa poboljšanom rastvorljivošću u vodi i postupak za dobijanje
CA2383298A1 (fr) Nouveaux derives d'.alpha.-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE314347T1 (de) Sulfonylderivate
BR0316574A (pt) Derivados de ácido acético 3-carbonil-1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
Fareed et al. Small-molecule direct antithrombins: argatroban
TW200510369A (en) Novel ethylenediamine derivatives
CA2343109A1 (en) Thrombin inhibitors
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
EE04564B1 (et) Bifenlamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning proflaktiline ja terapeutiline toimeaine tromboosi v?i emboolia vastu
EA200400545A1 (ru) Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
DE60128736D1 (de) Methode zur darstellung von (pyridyl substituierten)methyl-thio-benzimidazol-derivaten
Lu et al. Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy) ethyl] amino} carbonylmethyl-6-methyl-3-[2, 2-difluoro-2-phenylethylamino] pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif
JP2007508308A (ja) 第Ｘａ因子の阻害剤としてのチオエーテル置換されたベンズアミド誘導体
Markwardt et al. The antithrombotic effect of synthetic thrombin inhibitors
ATE35678T1 (de) Vinylcarbonsaeure-derivate und ihre herstellung.
ES2169909T3 (es) 5-hidroximetil-2-aminotetralinas como agentes cardiovasculares.
NO167147C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive tetrahydroisoksazolo(4,5-c)pyridinderivater.
SK96993A3 (en) Agent for production of drug with thrombolytic activity